Is GLP-1 covered by insurance for weight management?
GLP-1 receptor agonists — semaglutide and tirzepatide — are among the most expensive medications by monthly cost in the U.S. market. Brand-name semaglutide for weight management (Wegovy) has a list price of approximately $1,350 per month. Brand-name tirzepatide for weight management (Zepbound) carries a similar list price. Without insurance, those numbers are out of reach for most people.
The problem is that insurance coverage for weight management drugs is inconsistent and heavily plan-dependent. Many commercial insurance plans simply do not include anti-obesity medications on their formularies, treating weight management as an elective or lifestyle category rather than a chronic medical condition. Plans that do cover these drugs often require extensive prior authorization documentation. And even approved coverage frequently comes with step therapy requirements — showing that you have tried and failed other interventions first.
| Insurance type | Covers GLP-1 for weight management? | Key barriers |
|---|---|---|
| Commercial / employer plan | Sometimes — varies by plan | Prior auth, BMI threshold, step therapy |
| Medicare Part D | Limited — historically excluded | SSA exclusion for weight-loss drugs; partial changes in 2024–2026 |
| Medicaid | Varies by state | State formulary decision; prior auth common |
| Compounded GLP-1 (cash pay) | Never covered by insurance | Always out-of-pocket; $100–$350/mo typical; requires clinician Rx |
Commercial insurance: what typically qualifies for coverage
For commercial insurance plans that do cover GLP-1 medications for weight management, prior authorization criteria generally include:
- BMI threshold: Most plans require a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, or cardiovascular disease).
- Documentation of prior attempts: Many plans require evidence of previous participation in a structured weight management program or documentation of prior pharmacological treatment that failed.
- Prescriber documentation: The prescribing clinician typically must submit a letter of medical necessity with clinical justification, not just a prescription.
- Step therapy: Some plans require a trial of less expensive interventions before approving a GLP-1 medication.
Meeting these criteria is necessary but not sufficient — prior authorization approval is not guaranteed and denial rates for first submissions can be high. The appeals process adds additional weeks.
Medicare coverage: a limited and evolving picture
Medicare Part D historically has excluded drugs prescribed primarily for weight management under the Social Security Act, which prohibits coverage of drugs for “anorexia, weight loss, or weight gain.” This exclusion has blocked GLP-1 access for millions of Medicare beneficiaries with obesity.
The Treat and Reduce Obesity Act has been proposed in multiple congressional sessions to remove this exclusion, and some partial changes have moved forward. However, as of 2026, Medicare Part D coverage for GLP-1 medications used specifically for weight management remains limited. GLP-1 drugs for type 2 diabetes management may have different formulary status.
If you are on Medicare, check your specific Part D plan’s formulary for current coverage status, as policy and plan-specific coverage can change.
For most people seeking a GLP-1 for weight management rather than diabetes, coverage is frequently a “no” — or only a yes after a long fight.
Medicaid: state-by-state variation
Medicaid coverage for anti-obesity medications, including GLP-1 agonists, varies significantly by state. Some state Medicaid programs have added semaglutide or tirzepatide to their formularies for qualifying beneficiaries with obesity and comorbidities; others have not. Prior authorization requirements and eligibility criteria differ by state.
Your state Medicaid program’s pharmacy benefit page or your prescribing clinician can advise on whether these medications are covered in your state and what documentation is required to request coverage.
Employer plans: the most variable coverage tier
Employer-sponsored plans have wide latitude to include or exclude medications from their formularies. A 2024 analysis in JAMA Health Forum found that fewer than half of large employer plans covered GLP-1 medications for weight management, and coverage rates among smaller employers were lower. The variation reflects both cost concerns (these are high-cost drugs that significantly impact pharmacy budgets) and divergent views on classifying obesity as a medical condition requiring pharmaceutical treatment.
If you have employer-sponsored coverage, your HR department or your plan’s member portal can confirm whether GLP-1 medications are on the formulary and what tier they are on. A higher drug tier means higher cost-sharing even with coverage.
What are my options when insurance doesn’t cover GLP-1?
For most people who need GLP-1 therapy for weight management but cannot obtain insurance coverage, compounded semaglutide and tirzepatide from licensed 503A telehealth programs is the primary realistic pathway. Compounded formulations of these peptides are significantly less expensive than brand-name drugs — typically $100–$350 per month depending on dose and provider.
Compounded semaglutide and tirzepatide are not FDA-approved drugs. They are prepared by licensed 503A pharmacies in the USA under individual clinician prescriptions, from the same active peptide. The critical safety distinction is using a licensed domestic 503A pharmacy versus overseas or gray-market suppliers — there is no hidden overseas supply chain in a legitimate compounded program.
A telehealth program that includes a clinician consultation, prescription, and compounded dispensing from a licensed 503A pharmacy covers the same clinical infrastructure as an insurance-covered path — without the prior authorization delay.
You can read more about the compounded pathway on our semaglutide and tirzepatide pages.
Frequently asked questions
Is GLP-1 covered by insurance for weight loss?
Coverage varies significantly by plan. Many commercial insurance plans do not cover GLP-1 medications for weight management alone. Plans that do cover these drugs typically require documentation of a qualifying BMI (usually ≥30, or ≥27 with a weight-related comorbidity), prior authorization, and sometimes evidence of previous weight loss attempts. Approval is not guaranteed even when coverage exists in theory.
Does Medicare cover GLP-1 for weight loss?
Medicare Part D historically excluded weight management drugs. The Treat and Reduce Obesity Act and related legislation have been proposed to expand Medicare coverage, and some updates have occurred, but coverage remains limited and plan-dependent. Check your specific Part D plan formulary and consult your plan for current status.
Does Medicaid cover GLP-1 medications?
Medicaid coverage for GLP-1 medications varies by state. Some states cover semaglutide or tirzepatide for qualifying beneficiaries with obesity and comorbidities; others do not include these medications on their formularies. Your state Medicaid program or prescriber can advise on current formulary status.
What is prior authorization for GLP-1 and how do I get it approved?
Prior authorization (PA) requires your prescriber to submit documentation supporting medical necessity — typically your BMI, comorbidities, medications tried, and the requested drug and dose. PA criteria vary by insurer; approval rates and timelines also vary. Your prescriber or their office typically handles the submission; some practices have staff who specialize in PA appeals.
What if my insurance denies GLP-1 coverage?
You can appeal the denial — your insurer is required to provide a reason and an appeals pathway. If appeals fail, compounded semaglutide or tirzepatide from licensed 503A telehealth programs is the primary cash-pay alternative, typically at $100–$350 per month versus $800+ for brand-name drugs. HSA and FSA dollars can be used for prescription costs.
Will insurance cover GLP-1 for diabetes vs. weight loss?
Brand-name semaglutide at the diabetes dose (Ozempic) and tirzepatide at the diabetes dose (Mounjaro) typically have better formulary coverage under diabetes management benefits than weight-management formulations at higher doses. If you have a confirmed type 2 diabetes diagnosis, your coverage pathway may differ from a weight-management-only indication. Discuss with your prescriber which indication applies to your situation.